Biocatalysis is an attractive route for the synthesis of complex organic molecules, such as pharmaceuticals, due to the properties of enzymes (high specificity and high catalytic rate). Ideally, we would be able to use enzymes in continuous-flow reactors to benefit from the advantages of continuous-flow chemistry (flexibility, control, product stream purity, low capital cost and improved yields for some reactions). However, continuous-flow applications for biocatalysis face substantial technical obstacles, particularly for enzymes that require cofactors. In the work presented here we tackle two of these obstacles: the provision of cofactor and cofactor recycling in flow, and enzyme immobilization without loss of activity. This is achieved through the production of modular biocatalysts that retain and recycle their cofactors, and that allow orthogonal, site-specific covalent conjugation to a surface. This generalizable engineering approach allowed us to build a complex, multistep flow reactor that outperforms previously published systems for cofactor-dependent continuous-flow biocatalysis.
B iocatalysis is used for many chemical syntheses due to its high catalytic rates, specificities and operation under ambient conditions 1, 2 . Continuous-flow chemistry offers advantages for biocatalysis, avoiding the need for catalyst removal from the product stream and process issues caused by substrate/product inhibition, equilibrium controlled limitations on yield and allosteric control 3 . Modular continuous-flow biochemistry would also allow the flexible assembly of different complex multistep reactions 4 , including non-natural reaction combinations. Here we tackle some technical challenges that currently prohibit the widespread use of continuous-flow biocatalysis: cofactor immobilization and site-specific immobilization. We provide an example of enzymes engineered to retain and recycle their cofactors, and the use of these enzymes in continuous production of chiral pharmaceutical intermediates.
Enzyme immobilization for continuous-flow applications has been studied for some time; indeed, a number of industrial processes are currently based on such technologies [4] [5] [6] [7] [8] [9] . However, such processes have generally been limited to cofactor-independent enzymes, such as esterases. Cofactors, such as NAD + and ATP, are used stoichiometrically unless recycled, typically by a second enzyme: without recycling, cofactors become prohibitively expensive for most industrial syntheses. As cofactors require diffusion for recycling, they are ill-suited for use in continuous-flow reactors and the lack of a practical engineering solution for the issue has stymied the use of cofactor-dependent enzymes in continuous-flow applications 4 . Growing interest in immobilized biocatalysts for cell-free metabolic engineering 10 has led to the development of a variety of enzyme-cofactor-carrier combinations 11 , including attachment of PEGylated nicotinamide cofactors to the primary amine groups of individual dehydrogenase enzymes 12 , arrays of co-immobilized enzymes and swinging cofactors on DNA surfaces 13 , immobilization of flavoproteins onto flavin-decorated beads 14 and co-immobilization of enzymes and cofactors onto beads 15 .
Herein, we propose a generalizable chemical and genetic enzyme engineering approach that enables the fabrication of modular, multistep, biocatalytic, continuous-flow reactors using cofactor-dependent enzymes. We have exemplified this approach using a three-step cascade in which glycerol is phosphorylated, then oxidized to form dihydroxyacetone phosphate (DHAP), which is then used in an aldolase-dependent reaction to produce an advanced intermediate in the production of an antidiabetic drug (d-fagomine). Our model system exhibited excellent space-time yields (up to 70 g l −1 h −1 g −1 ) and total turnover numbers (TTNs; over 10,000) for the engineered biocatalysts.
Results
Design of biocatalysts that retain and recycle their cofactors. Our design for a self-contained biocatalyst that can retain and recycle its cofactor was inspired by enzymes that retain their substrates via covalent attachment during a reaction cascade involving multiple active sites, for example phosphopantetheine-dependent synthases [16] [17] [18] and lipoic acid-dependent dehydrogenases 19 . In such enzymes, the substrate is delivered from one active site to the next by a flexible, swinging arm that is covalently attached to the protein.
We have adopted a similar strategy, whereby a flexible swinging arm covalently attaches a cofactor to a synthetic, multidomain protein and delivers that cofactor to the different active sites of the fusion protein, allowing its simultaneous use and recycling, while preventing its diffusion (Fig. 1) .
The general design of our single-molecule biocatalysts is shown in Fig. 1 . Each biocatalyst is comprises three modules: a catalytic module that drives the desired synthesis reaction, a cofactor-recycling Engineered enzymes that retain and regenerate their cofactors enable continuous-flow biocatalysis module that regenerates the cofactor after use and an immobilization module that allows site-specific, covalent conjugation to an activated surface. The modular design is intended to allow a small number of immobilization and cofactor-recycling modules to be used with a wide variety of synthesis modules, thereby enabling diverse synthetic reactions using a relatively small library of core components. It is envisaged that multiple biocatalysts of this type could be combined in series or in networks for the synthesis of complex chiral molecules using multi-enzyme cascade reactions.
In our design, the three modules of biocatalyst were encoded by an open-reading frame for production in Escherichia coli as a single protein with a short spacer (2-20 amino acids) separating each module. A modified cofactor was designed that could be conjugated to the spacer between the catalytic and cofactor-recycling modules. We used a polyethylene glycol (PEG) for the flexible linker to allow movement of the modified cofactor between active sites. In silico modelling suggested that a chain length of 24 ethylene glycol units was long enough to allow ingress into both active sites. The amino acid spacer that separated the catalytic and cofactor-recycling modules contained a single solvent-exposed cysteine residue, which provided an accessible thiol group with which to tether the maleimide-functionalized PEGylated cofactor ( Fig. 1 ).
Assembling the biocatalysts.
For the prototype, we selected d-fagomine synthesis-coupling three catalytic steps in series to convert glycerol (1) and 3-aminopropanal (3) into a chiral drug precursor ( Fig. 2 ). Total synthesis of this antidiabetic piperidine iminosugar using non-biological catalysts is challenging, due to the complexity conferred by its two stereocentres and eight possible diastereomers, with even recent advances only resulting in yields up to 65% of each diastereomer 20 . In our process, glycerol is converted to DHAP (4) by regiospecific phosphorylation and oxidation, via ATP and NAD +dependent steps, respectively. A subsequent aldolase-catalysed stereoselective aldol addition with 3-aminopropanal yields (3S,4R)amino-3,4-dihydroxy-2-oxyhexyl phosphate (3S,4R-ADHOP), which can be dephosphorylated with phosphorylase and cyclized to form d-fagomine 21 (6) . For the purposes of purification, we elected to use the carboxybenzyl (Cbz)-protected derivative of 3-aminopropanal, yielding N-Cbz-3S,4R-amino-3,4-dihydroxy-2-oxyhexyl phosphate (N-Cbz-3S,4R-ADHOP) (5) .
Prior comparison of enzymes that could be used for the first two steps of the model synthesis 22 had suggested that the most suitable enzymes for glycerol phosphorylation were a Thermococcus kodakarensis glycerol kinase (GlpK Tk ) and a Mycobacterium smegmatis acetate kinase (AceK Ms ). For the NAD + -dependent production of Each biocatalyst comprises a genetically encoded multi-enzyme fusion protein capable of retaining and recycling a tethered cofactor. There are three protein modules: a cofactor-dependent catalytic enzyme module (purple), a cofactor-recycling module (pink) and a conjugation module (orange) with short amino acid spacer regions between these modules (see Methods for details). A cofactor that has been modified by amine activation to allow for linker installation (A) is tethered to the protein through a maleimide-thiol conjugation via a solvent-exposed cysteine located in the spacer region between the catalysis and recycling domains (B). The conjugation module allows immobilization of the biocatalyst via the formation of a covalent bond between a surface attached TFK (C) and the active site serine of the esterase (D).
DHAP from glycerol-3-phosphate (G3P), E. coli glycerol-3-phosphate dehydrogenase (G3PD Ec ) and the water-forming NADH oxidase from Clostridium aminovalericum (NOX Ca ) were selected. The third reaction step is a cofactor-independent aldolase-catalysed aldol addition. A monomeric fructose aldolase (FruA) homologue from Staphylococcus carnosus was selected from a panel of five potential aldolases. Each of the enzymes incorporated into the fusion proteins were selected for their compatibility in batch reactions 22 , high catalytic rates, relatively simple quaternary structures and thermostability (Supplementary Table 1 ).
For the conjugation module, we used a serine hydrolase enzyme coupled with a suicide inhibitor (trifluoroketone (TFK)) that forms a site-specific and stable covalent bond between the inhibitor and the catalytic serine residue 23 . Esterase E2 from Alicyclobacillus acidocaldarius (E2 Aa ) 24 was selected for the serine hydrolase component as a highly stable, soluble, monomeric protein (Supplementary Table 1 ).
The genes encoding GlpK Tk and AceK Ms were fused, such that GlpK Tk formed the N terminus of the resultant protein and AceK Ms formed the C terminus (Fig. 2 ). The two modules were separated by a 19 amino acid unstructured amino acid linker, containing a single, solvent-accessible cysteine residue that was used subsequently as the attachment point for the maleimide-functionalized PEG 24 
. A similar gene fusion was constructed used G3PD Ec and NOX Ca , producing a protein in which G3PD Ec formed the N terminus and NOX Ca formed the C terminus. The fused proteins retained or in some cases improved their original catalytic functions (Table 1) , albeit some loss of activity (both K M and k cat ) was incurred for AceK Ms and G3PD Ec . The thermal stability of each of the fused enzymes appeared to be independent of one another; that is, protein unfolding of the component modules of each fusion are independent events (Supplementary Table 1 ).
The gene encoding the conjugation module (E2 Aa ) was fused with both the glpK Tk -aceK Ms and g3pD Ec -nox Ca such that it formed the C terminus of the encoded proteins (that is, GlpK Tk -AceK Ms -E2 Aa and G3PD Ec -NOX Ca -E2 Aa ). Addition of the conjugation module had little effect on the kinetic performance or thermal stabilities of the other modules (Table 1 and Supplementary Table 1 ). The conjugation module was highly efficient (86-98% immobilization efficiency) and the immobilized enzymes retained their activities ( Supplementary  Fig. 6 ). This immobilization technique has the potential for broad applicability to other immobilized biocatalytic systems, in line with similarly successful orthogonal or self-immobilizing techniques using Spy, Halo or streptavidin protein motifs 25 , or indeed immobilization of flavoenzymes via their flavin cofactors 14 . The cofactors were modified by functionalization of the C6-adenine-amine of ADP (7) or NAD + (12) to which a modified PEG 24 was added ( Fig. 1 and Supplementary Fig. 2 ). The PEG 24 linker included an N-hydroxysuccinimide ester that allowed reaction with the modified cofactor and a maleimide group for conjugation with the fusion proteins. Conjugation of MAL-PEG 24 -2AE-ADP (11) and MAL-PEG 24 -2AE-NAD + (13) to the fusions yielded enzymes that were active in batch reactions without the addition of exogenous cofactor, with catalytic constants equivalent or superior to individual enzyme components (Table 1 and Supplementary Fig. 3 ). Mass spectrometry of cofactor-conjugated proteolysed fusion proteins indicated that the cysteine in the linker between the catalytic and cofactor-recycling modules reacted preferentially with the PEG 24maleimide modified cofactors ( Supplementary Fig. 4 ). Close to 100% of the target cysteine residue was conjugated with the modified cofactor for both fusions (97% for G3PD Ec -NAD teth -NOX Ca -Est2 Aa and up to 80% for GlpK Tk -ADP teth -AceK Ms -Est2 Aa ).
Performance of the three-step cascade. The fusion proteins with conjugated cofactors were immobilized on TFK-activated agarose beads at densities of 1.6, 1.0 and 1.0 mg of protein per g of wet beads for the phosphorylation, oxidation and aldolase biocatalysts, respectively, and packed into glass columns to produce three packed-bed reactor columns: a phosphorylation reactor (23.1 ml packed volume), an oxidation reactor (25.7 ml packed volume) and an aldol addition reactor (17.7 ml packed volume) ( Fig. 2) .
Individual performance data for each reactor (Fig. 3 ) revealed that the maximum space-time yields obtained ranged from ~11 mg l −1 h −1 mg −1 (mg of product per litre per hour per mg of protein) for the oxidation reactor to ~70 mg l −1 h −1 mg −1 for the phosphorylation reactor, with the aldol addition reactor yielding ~30 mg l −1 h −1 mg −1 . This is consistent with the expected yields based on k cat /K M values of the loaded enzymes ( Table 1) ; for example, for the phosphorylation reactor, 36.9 mg protein per column (2.7 nmol tethered biocatalysts) yielded 2.6 g product per litre (6.6 mM) per hour, equivalent to the expected 1,399 nmol per nmol of enzyme per second.
As reported elsewhere, when the G3P oxidation reaction and aldolase reaction were run in batch, yields were limited by product inhibition and substrate: product equilibrium, with substrate conversions of 88% and 63%, respectively 22, 26, 27 . In our reactors, the phosphorylation and oxidation reactions were run to completion (that is, complete 100% substrate conversion). It is likely that running the system as a continuous-flow reaction prevented the buildup of reaction products and so mitigated both product inhibition and equilibrium control, which limited yield in batch reactions. These effects probably stem from the inherent advantages of continuous-flow biocatalysis, namely increased surface area of the catalyst, micromixing and removal of product concentrations from the protein active site to drive the reaction and avoid product inhibition, as well as enhanced mass transfer (reduced distances required for substrate diffusion) 9 . The TTNs for the cofactors exceeded 10,000 (~11,000 for the NAD + -dependent oxidation reactor and ~17,000 for the ATPdependent phosphorylation reactor; Fig. 3a ). This is at least 100 times greater than reported for other systems using cofactor-dependent enzymes in continuous flow ( Table 3 ). The highest TTN that we are aware of is for a recently reported, innovative closed-loop system, where separation and recirculation of the cofactors can increase TTN by up to 20-fold 28 . The system reported herein exhibits 5-8-fold higher TTN than this system (Table 3 ). In each case, the reactions stopped because of the inactivation of one of the enzymatic modules (AceK Ms for the phosphotransfer reactor; G3PD Ec for the oxidation reactor) rather than the loss of cofactor. This was evidenced by the resumption of catalytic activity for the respective reactor on provision of either stoichiometric amounts of ATP/ NADH or supplementation of the inactive enzymes, but not with supplementation of stoichiometric amounts of ADP/NAD + (see Methods). Liquid chromatography-mass spectrometry (LC-MS) proteomic analysis also indicated that the cofactors remained tethered to the fusion proteins many months after reactor assembly and use ( Supplementary Fig. 8 ). It is reasonable to assume that the turnover numbers would be higher if the enzymes were modified for greater stability, using modern enzyme engineering approaches 29, 30 .
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GlpK The three reactors were combined in series ( Fig. 2b) , with glycerol fed to the first reactor (the phosphorylation reactor) and a feed of Cbz-protected aldehyde entering the system between the oxidation and aldol addition reactors. When run at 0.3 ml min -1 , between 83% and 98% of glycerol was converted to enantiomerically pure N-Cbz-3S,4R-ADHOP in a single passage through the reactor ( Fig. 3 ; the product was confirmed by high-performance liquid chromatography (HPLC), LC-MS and 1 H-NMR analysis; Supplementary  Fig. 8 ). It is likely that complete conversion to the aldol product could be achieved with further balancing of the reactor flow rates, as the unconverted fraction consisted of excess G3P produced by the phosphotransfer reactor. The percentage conversion dropped to 40% at higher flow rates (1.0 ml min −1 ), albeit this could be improved through reactor engineering (longer columns, greater biocatalyst loading, higher surface area, multiple passages through the reactor and so on). The entire system was stable for operation for three runs of 8 h at room temperature (23 °C) with storage at 4 °C between runs, remaining functional for up to 5 d in this manner. Individual reactors remained stable for differing, longer times (see Methods).
A comparison of our system with similar biocatalytic systems used to produce non-natural carbohydrates ( Table 2) illustrates the advantage of continuous-flow biocatalysis for this reaction, with superior performance from both our system and a continuous-flow system using phosphatase and aldolase 31 when compared to multienzyme batch reactions. Our system offers further advantages in that there is no requirement to add cofactor to the substrate feed, allowing for cost savings from both reduced reagent input and the purity of the resulting product stream. In addition, the system reported here has superior space-time yields compared to any of the other systems.
Cofactor immobilization has been employed before, although in such examples the cofactor is not conjugated to a specific amino acid residue within a multi-enzyme fusion. Modified PEGylated NAD + has previously been bound to malate and glucose dehydrogenase enzymes via non-specific conjugation to solvent-exposed primary amines. Resulting enzyme-cofactor conjugates had an estimated average of six molecules of bound active NAD + per tetrameric enzyme. However, there was a substantial loss in catalytic activity towards the modified cofactor (alkylated at the 6-amino group) when compared to unmodified NAD + (26% and 36% retention of activity for malate and glucose dehydrogenase, respectively) 32 . Combining the soluble glucose dehydrogenase-NAD + conjugate with unmodified lactate dehydrogenase (to recycle the cofactor) in a continuous-flow system allowed for continuous conversion of pyruvate to l-lactate with ~20% conversion yields (1.1 mM from 5 mM substrate) for 16 h (ref. 32 ).
Co-immobilization of enzymes with reversibly immobilized cofactors onto agarose microbeads with crosslinking provided by polyethyleneimine has also been demonstrated for a coupled alcohol dehydrogenase-formate dehydrogenase system, applied to the asymmetric reduction of ketones to chiral alcohols 15 . However, the non-specific immobilization resulted in a significant loss in enzyme activity and only a modest number of total cofactor turnovers. After 92 h of continuous-flow operation, this system yielded just 85 turnovers per NAD + compared to 10,000 turnovers in our system ( Fig. 3) 15 . Other systems have used DNA to scaffold glucose and malate dehydrogenase in proximity to immobilized, modified NAD + , which had been attached to the DNA scaffold via an single-stranded DNA linker. This led to an improvement in catalytic activity, resulting from the forced proximity of the enzyme and cofactor. However, this system has not yet been applied to continuous-flow biocatalysis 13 .
Conclusions
We have developed and successfully implemented a general protein engineering strategy that enables cofactor-dependent, Continuous flow with enzyme fusions that retain and recycle their cofactors continuous-flow biocatalysis by the use of single-molecule multi-enzyme biocatalysts that retain and recycle their cofactors. The engineered biocatalysts were used to construct a threestep continuous-flow reactor system that performed well, with superior yields of d-fagomine precursor compared to chemical syntheses 20 , as well as high space-time yields and TTNs for the catalysts and cofactors. Additionally, use of the biocatalysts in a continuous-flow system appears to have mitigated production inhibition and equilibrium control of yield, allowing very high substrate conversion. We have used sugar analogue synthesis as a model for our prototype; however, we believe that this approach is generalizable because of the modular design principles used. For the biocatalysts, we envision a small library of conjugation and cofactor-recycling modules that could be used in conjunction with a larger library of catalysis modules to provide access to a wide range of reactions. For example, whilst we have chosen to demonstrate stereoselective aldol addition with the fructose-1,6-biphosphate aldolase FruA, use of the three other classes of DHAP-dependent aldolases (fuculose-1-phosphate FucA, rhamnulose-1-phosphate aldolase RhuA, tagatose-1,6-biphosphate aldolase TagA) 27 for the aldol addition reactor could be employed to generate all four ADHOP diastereomers with simple flow-path changes. The molecular modularity is mirrored in the flow reactor design, providing a flexible platform for building complex, multistep biochemical pathways with both serial and parallel reactor compartments that could be extended into the development of artificial metabolic networks.
Methods
General. Unless otherwise stated, chemicals were purchased from Sigma-Aldrich. All enzymes used for DNA manipulation were purchased from New England Biolabs, and expression vectors were purchased from Invitrogen unless otherwise stated. All PEG compounds were purchased from Quanta BioDesign Ltd.
NMR spectra were recorded with a Bruker Avance 400 MHz spectrometer in the deuterated solvents. Chemical shifts were calibrated against residual solvent peaks and are quoted in ppm relative to tetramethylsilane.
Unless otherwise specified, analytical HPLC was performed with a Waters Alliance e2695 Separations Module equipped with Waters 2998 PDA and Acquity QDa detectors, using a Waters XBridge BEH C18 column, 130 Å, 3.5 µm, 2.1 × 50 mm 2 with a 0-90% CH 3 CN gradient in 0.1% formic acid (unless otherwise specified).
Semipreparative, reversed-phase HPLC was undertaken using a Shimadzu SPD-10A ultraviolet-visible detector with ultraviolet detection at wavelength λ = 260 nm. The system was equipped with a Shimadzu 322 pump and Gilson 255 Liquid Handler and set at a flow rate of 10 ml min −1 . Peak separation was achieved using a Vydac 218TP1022 C18, 10 µm, 22 × 250 mm 2 column. Solvent gradients used Milli-Q water with 0.1% TFA (buffer A) and acetonitrile with 0.1% TFA (buffer B), with a gradient of 0-70% buffer B unless otherwise specified.
Biocatalytic reactor flow rates and mixing used a modified Biologic DuoFlow system with a Biologic Fraction Collector (Bio-Rad) using Biologic DuoFlow software v.5.10 Build 2 (Bio-Rad).
Structural modelling. Structure modelling was performed using Accelrys Discovery Studio 3.5. A model of G3PD Ec (based on Protein Data Bank (PDB) ID 1TXG) was oriented with its C-terminal residue in proximity to the N terminus of a model of Nox Ca (based on PDB ID 2CDU) with sufficient distance to conservatively avoid any steric contact between the two homodimeric proteins. A linker that maintained this distance (GSSGSSGSSCGSSGSSGSS) and a central cysteine for tethering NADH was constructed between the two termini. The cofactor was modelled into the active sites of 1TGX and 2CDU individually; the nicotinamide cofactor position in Nox Ca was based on the position of ADP in the 2CDU crystal structure. The nicotinamide docking position in the G3PD Ec was inferred from that of the G3PD from Thermotoga maritima (PDB ID 1Z82) that was superposed with 1TXG to obtain the correct orientation.
A tether was constructed between the cysteine thiol of the linker to the -NH 2 group of the nicotinamide moiety, using the most distant of the homodimer monomers in both cases. The tether was subjected to an energy minimization using the Discover module implemented in Accelrys Materials Studio before finalizing the sequence. The length of the PEG linker (PEG24) used in the fusion proteins was selected on the basis of this modelling.
DNA manipulation. The pAF1 vector that encodes the DHAP-dependent fructose-1,6-biphosphate aldolase from Staphylococcus carnosus was a gift from A. Frazer (University of Manchester, Manchester, UK). The characteristics of enzymes used in this study are given in Supplementary Table 1 , and their genes were synthesized by GeneArt (ThermoFisher Scientific), unless otherwise stated, then cloned into pETCC2 (ref. 26 ) using appropriate restriction enzymes (Supplementary Table 2 ). Two versions of the genes encoding the FruA, the GlpK Tk -AceK Ms and the G3PD Ec -NOX Ca fusions were synthesized: one terminating in a STOP codon, and another in which the stop codon was omitted and a 3&' Sph 1 site was included to allow construction of the fusions that included the conjugation domain. The latter versions were cloned into pETCC2 containing the esterase e2 Aa gene to create an in-frame fusion with a short Gly-Ser repeat spacer. Accession numbers for all of the genes used are given in Supplementary Table 2 . Table 2 ) of the purified proteins was characterized. Cells were ruptured by passage three times through an EmulsiFlex-C5 cell homogenizer at 15,000 psi and 4 °C and cellular debris removed by centrifugation (40,000g, 15 min, 4 °C). The lysate was filtered (0.45 μm) and applied to a 5 ml HisTrap FF column equilibrated in 50 mM Tris, 300 mM NaCl pH 8 containing 0.1 mM tris(2-carboxyethyl)phosphine (TCEP). The column was washed with 40 mM imidazole in the same buffer then the bound protein eluted with 300 mM imidazole in the same buffer. The eluted protein was analysed by gel filtration on a Superdex 200/1030 gel filtration column (GE Healthcare) equilibrated with PBS with the absorbance of the eluted protein monitored at 280 nm ( Supplementary  Fig. 1 ) and the esterase activity in the eluted fractions determined.
Small
Production of GlpK
Production of G3PD Ec -NOX Ca -Est2
Aa . E.coli BL21 DE3 Star containing pCJH8 were cultured in an XRS 20 bioreactor (Pall Corporation) using a 2 l volume of M9 minimal medium, with 1% (w/v) ammonium sulfate and 1% (w/v) glucose as nitrogen and carbon source, respectively, and supplemented with 100 µg ml −1 ampicillin. After initial growth at 37 °C, the temperature was reduced to 25 °C before induction, when the OD 600 reached 2.2. The OD 600 of the culture at induction was 2.9 and 1.6 ml of 20% arabinose and IPTG to 1 mM were added to induce. The glucose feed was started 7 h postinduction to maintain 1% glucose and cells were harvested 22 h postinduction, when OD 600 was 21.6.
Cells were ruptured and the protein purified as described for GlpK Tk -AceK Ms -E2 Aa and FruA Sc -Est2 Aa , except that 50 mM citrate and 200 mM NaCl pH 6 containing 1 mM TCEP was used for the gel filtration step. The absorbance of the eluted protein was monitored at 280 and 450 nm ( Supplementary Fig. 1) .
Synthesis of N 6 -2AE-ADP and MAL-PEG 24 -2AE-ADP.
Adenosine-5&'diphosphate sodium salt, ADP.xNa, (0.5 g, 1.13 mmol) was dissolved in distilled deionized water (1.5 ml) and ethyleneimine (160 µl) was added slowly. During the addition of the ethyleneimine, the pH was carefully adjusted with perchloric acid to keep it within the pH range of 2.0-4.0. The pH at the end was left at 3.2. The reaction was stirred at room temperature for ~50 h. The solvent was then evaporated in a fume-hood under a stream of nitrogen. The crude residue was dissolved in deionized water (10 ml) and the pH adjusted to 5.6 by the addition of lithium hydroxide (LiOH; saturated aqueous solution) and heated at 35 °C for 80 h. The solution was lyophilized to yield crude N 6 -2AE-ADP ( Supplementary Fig. 2) .
Crude N 6 -2AE-ADP DIPEA salt (100 mg, crude estimate equivalent to about 13.7 mmol pure 2AE-ADP) was dissolved in 50% acetonitrile/PBS pH 7.0 (3.0 ml) and a solution of MAL-PEG 24 -NHS (43.0 mg) was added and stirred at room temperature overnight ( Supplementary Fig. 2) . The mixture was purified by preperative HPLC and lyophilized to yield pure MAL-PEG 24 -2AE-ADP (12.2 mg).
Tethering of MAL-PEG 24 -2AE-ADP to GlpK Tk -AceK Ms -Est2 Aa . IMAC purified GlpK Tk -AceK Ms -Est2 Aa was treated with TCEP (0.1 mM) then reacted with ten equivalents of MAL-PEG 24 -2AE-ADP without removal of the TCEP and washed with PBS. The tethered 2AE-ADP-PEG 24 -MAL-GlpK Tk -AceK Ms -Est2 Aa was found to convert 10 mM glycerol and 10 mM acetyl phosphate to G3P with high efficiency ( Supplementary Fig. 3a) .
Synthesis of N 6 -2AE-NAD + and MAL-PEG 24 -2AE-NAD + .
To a solution of β-nicotinamide adenine dinucleotide hydrate NAD + (1.0 g, 1.51 mmol) dissolved in 2 ml of deionized water, ethyleneimine (4.25 mmol) was added dropwise, with the solution maintained at a pH of 3.2 with the addition of 70% perchloric acid. The reaction mixture was stirred at room temperature for 50 h with the pH maintained at 2-3, before the addition of 1.75 ml of deionized water to solubilize the precipitate. The product was precipitated by the addition of ice-cold ethanol and the precipitate washed with ethanol. The resulting mix of N1-2AE-NAD + and NAD + was dissolved in water (10 ml) and adjusted to pH 6.5 with 0.1 M LiOH. The solution was stirred at 50 °C for 7 h with the pH maintained at 6.5 before being lyophilized to yield the product, as a mixture of N 6 -2AE-NAD + and NAD + ( Supplementary Fig. 2) .
To a stirred solution of N 6 -2AE-NAD + /NAD + (14.7 mg mix, approximately 0.0104 mmol N 6 -2AE-NAD + ) in PBS (pH 7.4, 1.0 ml) was added a solution of MAL-PEG 24 -NHS (17.4 mg, 0.0124 mmol) in PBS (1 ml). The solution was stirred at room temperature overnight ( Supplementary Fig. 2) . The mixture was analysed by HPLC (0 → 50% CH 3 CN + 0.1% TFA over 18 min). Analysis of a peak with a retention (R t ) of 17.8 min by electrospray ionization in positive mode (ESI+) found a compound with a mass consistant with that of the desired product (m/z of 662.62 for M+3 (calculated 662.65) and 993.42 for M+2 (calculated 993.98)). The mixture was purified by preparative HPLC and fractions at R t = 17.8 min combined and lyophilized to yield pure MAL-PEG 24 -2AE-NAD + (5.4 mg, 26%).
Tethering of MAL-PEG 24 -2AE-NAD + to G3PD Ec -NOX Ca -Est2 Aa . G3PD Ec -NOX Ca -Est2 Aa was desalted into PBS containing 0 mM, 0.1 mM or 1 mM TCEP and reacted with 1-200 equivalents of MAL-PEG 24 -2AE-NAD + . The reaction mixtures were analysed by SDS-PAGE and the conjugate from one condition (0.1 mM TCEP, 200 equivalents TCEP) analysed by mass spectrometry. The tethered 2AE-NAD + -PEG 24 -MAL-G3PD Ec -NOX Ca -Est2 Aa was found to convert 10 mM G3P and to DHAP with high efficiency ( Supplementary Fig. 3b ).
Proteomic analysis of MAL-PEG 24 -2AE-NAD + tethered to G3PD
Ec -NOX Ca -Est2 Aa by LC-MS. The accurate mass of G3PD Ec -NAD teth -NOX Ca -Est2 Aa conjugate was determined by denaturing LC-MS ( Supplementary Fig. 4 ). Protein samples were spiked with formic acid to a final concentration of 0.1% (v/v) and separated by reverse-phased liquid chromatography on an UltiMate 3000 RSLC nano system (ThermoFisher Scientific) fitted with a 50 × 4.6 mm 2 , 5 μM particle size, 300 Å pore size PLRP-S column (Agilent). Proteins were eluted at a flow of 250 μl min −1 by applying a linear 30 min gradient from 0% to 80% solvent B (mobile phase A, 0.1% (v/v) formic acid; mobile phase B, 90% (v/v) acetonitrile/0.1% (v/v) formic acid) using an Apollo II electron spray ion source coupled to a microTOF-QII mass spectrometer (Bruker). The instrument was calibrated in positive ion mode using ESI-L Low Concentration Tuning Mix (Agilent) and LC-MS raw data were processed and deconvoluted using the MaxEnt algorithm as part of Bruker Compass DataAnalysis v.4.3.
Sample preparation and peptide sequencing by nanoUltra Performance Liquid
Chromatography-MS-MS. G3PD Ec -NAD teth -NOX Ca -Est2 Aa protein bands were manually excised from Coomassie-stained SDS-PAGE gels and subjected to manual in-gel reduction, alkylation and tryptic digestion. All gel samples were reduced with 10 mM dithiothreitol (Sigma) for 30 min, alkylated for 30 min with 50 mM iodoacetamide (Sigma) and digested with 375 ng trypsin gold (Promega) for 16 h at 37 °C. Peptides then were separated using an UltiMate 3000 RSLC nano system (ThermoFisher Scientific), using a 60 min gradient on an Acclaim Pepmap 100 column (50 cm × 75 µm internal diameter with 3 µm particles). High-resolution MS/MS data was obtained on an Orbitrap Fusion Lumos Mass Spectrometer operated in data-dependent mode, automatically switching between the acquisitions of a single Orbitrap MS scan (resolution, 120,000) every 3 s and the top-20 multiply charged precursors selected for EThcD fragmentation with a resolution of 30,000 for Orbitrap MS-MS scans.
Mass spectra database searching. Orbitrap MS/MS data were searched against a focused decoy database containing G3PD Ec -NOX Ca -Est2 Aa and common contaminant protein sequences using the Byonic search engine (Protein Metrics) with a tolerance of 5 ppm for precursor ions and 10 ppm for product ions. Enzyme specificity was tryptic and allowed for up to two missed cleavages per peptide. A wildcard search with a range of +75 to +2,200 Da facilitated confident peptide identification (<1% false discovery rate) and spectrum counting of PEGylated cysteine residues. Variable modifications were set for NH 2 -terminal acetylation or protein N termini, oxidation of methionine or tryptophan, and carbamidomethyl modification of cysteine ( Supplementary Fig. 4 ).
Synthesis of thiohexyltrifluoroketone (hTFK) and hTFK-vinyl sulfone activated beads.
To a stirred mixture of NaHCO 3 (4 mmol) in anhydrous dichloromethane (8 ml), 1,6-hexanedithiol (601 mg, 0.612 ml, 4 mmol) was added under a nitrogen atmosphere. Bromotrifluoroacetone (0.415 ml, 0.4 mmol) was then added dropwise. The reaction was monitored by thin layer chromatography. The reaction mixture was stirred under N 2 for 5 d at room temperature and then poured into 50 ml of water. After extraction with ether (3 × 30 ml), the organic solvent was dried (MgSO 4 ) and the solvent removed under reduced pressure. hTFK was characterized by LC-MS; analytical HPLC (20-80% gradient MeCN into H 2 O, 0.1% TFA) gave a single peak at 6.6 min (λ = 214 nm), >90% purity; ESI (negative scan mode) found 259.16 amu; calculated molecular weight of 260.33. hTFK could be used directly in loading the divinyl sulfone (DVS)-modified beads.
Four per cent crosslinked agarose (Sepharose CL-4B, GE Healthcare) was functionalized by treatment with DVS to yield the vinyl sulfone decorated agarose as an aqueous slurry with vinyl sulfones at approximately 1 mmol ml −1 of slurry. To 500 g of damp drained Sepharose CL-4B was added 500 ml of 0.5 M Na 2 CO 3 (pH 12) and 5,000 µl of DVS. The resulting suspension was stirred gently for 70 min at room temperature before being washed extensively with water. The solution was stored as a 1:1 w/v slurry in 50% ethanol/water. Activated DVS-agarose was then reacted with hTFK at approximately 5 molar per cent ratio for between 6 h and overnight before capping all remaining vinyl sulfone functionalities with 2-mercaptoethanol. Saturated NaHCO 3 solution (20 ml) and hTFK (1.2 ml ethanol solution containing 26 mg of compound, 0.1 mmol, 5% loading) were added to the DVS resin (200 ml, 16-20 mmol, 50% slurry in 1:1 ethanol/water) and stirred at room temperature for 2 h; excessive reactive sites were blocked by the addition of β-mercaptoethanol (2.8 ml, 40 mmol) and washed with 50% ethanol/water until no smell was evident. The hTFK-loaded agarose gel obtained was filtered, washed and stored as a 1:1 slurry in 50% ethanol/water for further use. The synthesis scheme is summarized in Supplementary Fig. 5 .
Assembling the phosphotransfer reactor. Forty milligrams of GlpK Tk -AceK Ms -Est2 Aa (296 nmol) was immobilized onto 25 g of Sepharose-hexyl-DVS-TFK beads. GlpK Tk -AceK Ms -Est2 Aa was immobilized with 98.2% efficiency and retained 95.3% glycerol phosphorylation catalytic activity compared to non-immobilized controls in batch reaction ( Supplementary Fig. 6 ). The immobilized GlpK Tk -AceK Ms -Est2 Aa was treated with 0.1 mM TCEP, washed with PBS containing 0.5 mM EDTA then reacted with six equivalents of MAL-PEG 24 -2AE-ADP for 6 h at 4 °C before being washed with reaction buffer (0.2 M sodium citrate buffer pH 7.9). The resultant beads were analysed for glycerol kinase activity in the presence and absence of ATP in batch reactions, and demonstrated to have ~30% tethering efficiency (activity without added ADP calculated as the percentage of activity with added ADP). The beads were then packed into a 25 × 15 mm 2 Benchmark column (Kinesis, Australia) to a packed-bed volume of 21.2 ml and the activity of the column was determined ( Supplementary Fig. 7) .
A bioreactor packed with the immobilized GlpK Tk -ATP teth -AceK Ms -Est2 Aa nanomachine beads was found to convert 10 mM glycerol and 10 mM acetyl phosphate to G3P and acetate with approximately 60% efficiency at an optimal flow rate of 0.25 ml min −1 (Supplementary Fig. 8 ). This resulted in a space-time yield of 70 mg G3P l −1 h −1 per mg protein. The bioreactor stability was further assessed by continuing to run the phosphotransfer reactor for a total time of 870 min resulting in a total 14,222 turnovers of the tethered cofactor (Fig. 3) . In order to assess the factors affecting loss of activity within the phosphotransfer reactor, the reactor was then run with supplementation of either 10 mM ATP, 10 mM ADP or catalytic amounts of either AceK Ms or GlpK Tk . Activity could be restored with addition of ATP but not with addition of ADP or addition of AceK Ms , suggesting that the GlpK Tk enzyme domain remained active and the ADP remained tethered to the nanomachines (later confirmed by proteomics analysis), and that AceK Ms had lost enzymatic activity and could no longer regenerate ATP from ADP.
Assembling the oxidation reactor. Eighty milligrams of G3PD Ec -NOX Ca -Est2 Aa (647 nmol; 1,260 esterase U) was immobilized onto 80 g of Sepharose-hexyl-DVS-TFK. G3PD Ec -NOX Ca -Est2 Aa was immobilized with 86% efficiency and retained 92% G3P oxidation activity compared to non-immobilized controls in batch reaction ( Supplementary Fig. 6 ). The immobilized G3PD Ec -NOX Ca -Est2 Aa was treated with TCEP, washed with degassed, sparged PBS containing 0.5 mM EDTA then reacted with six equivalents of MAL-PEG 24 -2AE-NAD + for 6 h at 4 °C before being washed with PBS. The resultant beads were analysed for G3P dehydrogenase activity in the presence and absence of NAD + in batch reactions, and demonstrated to have ~80% tethering efficiency (activity without added NAD + calculated as the percentage of activity with added NAD + ). The beads were then packed into a 250 × 15 mm 2 Benchmark column (Kinesis, Australia) to a packed-bed volume of 28.3 ml and the activity of the column was determined ( Supplementary Fig. 7) .
A column packed with the adsorbent was found to convert 10 mM G3P to DHAP with about 40-50% efficiency at a flow rate of 0.25 ml min −1 ( Supplementary  Fig. 8 ). This resulted in a space-time yield of 2.60 mg DHAP l −1 h −1 per mg protein.
The bioreactor stability was further assessed by continuing to run the oxidation reactor for a total time of 600 min resulting in a total 1,843 turnovers of the tethered cofactor (Fig. 3) .
In order to assess the factors affecting loss of activity within the oxidation reactor, the reactor was then run with supplementation of either 10 mM NAD, 10 mM NADH or catalytic amounts of either G3PD Ec or NOX Ca . Activity could not be restored with addition of NAD or NADH, suggesting that the G3PD Ec enzyme domain had lost enzymatic activity and could no longer catalyse the conversion of G3P to DHAP. The NAD remained tethered to the nanomachines, as was later confirmed by proteomics analysis (Supplementary Fig. 4 ).
Assembling the aldol addition reactor. Twenty milligrams of FruA Sc -Est2 Aa was reacted with 20 g of Sepharose-hexyl-DVS-TFK beads; FruA Sc -Est2 Aa was immobilized with 89% efficiency and retained 68% aldol addition activity compared to non-immobilized controls in batch reaction ( Supplementary Fig. 6 ). The resultant beads were then packed into a 150 × 15 mm 2 Benchmark column (Kinesis, Australia) to a final depth of 10 cm (17.7 ml packed-bed volume) and the activity of the column was determined ( Supplementary Fig. 7 ).
Enzyme assays. Glycerol kinase assays were performed at room temperature in 1 ml volume with direct detection of ADP and ATP by HPLC analysis of reaction supernatant. A typical reaction contained 1 mM glycerol, 10 mM MgCl 2, 50 mM NaHCO 3 buffer pH 9.0 and 1 mM ATP with approximately 2 µg ml −1 enzyme (~35 nM). Acetate kinase assays were conducted in the same manner as the glycerol kinase assays described above, replacing ATP with ADP, and glycerol with acetyl phosphate. Kinetics were determined by varying the concentration of ATP or glycerol for glycerol kinase and ADP and acetate for acetate kinase, whilst maintaining the concentration of the other substrate in excess.
NADH oxidase activity was determined from the oxidation of 0.1 mM NADH in 50 mM sodium phosphate pH 7 containing 1 mg ml −1 BSA, with the loss of NADH monitored spectroscopically at 340 nM (ε 340 nm = 6.22 mM −1 cm −1 ), with one unit of NADH oxidase activity defined as the amount required to oxidize 1 μmol NADH in 1 min at ambient temperature.
G3P dehydrogenase activity was determined from the oxidation of G3P to DHAP in 50 mM sodium phosphate pH 9.0 for individual enzyme assays, or at pH 8.0 for combined multi-enzyme reactions, with the reaction progress followed by monitoring the production of NADH spectroscopically at 340 nM, or by direction detection of both G3P and DHAP by LC-MS, with one unit of G3P activity defined as the amount required to oxidize 1 μmol G3P in 1 min at ambient temperature.
Esterase activity was determined from the hydrolysis of p-nitrophenyl acetate (Sigma) in 50 mM sodium phosphate pH 7 containing 1 mg ml −1 BSA and with a typical reaction containing 0.4 mM p-nitrophenyl acetate. The hydrolysis of p-nitrophenyl acetate was determined spectroscopically by the increase in absorbance at 405 nm due to production of p-nitrophenol (ε 405 nm = 18 mM −1 cm −1 ), with one unit of esterase activity defined as the amount required to hydrolyse 1 μmol p-nitrophenyl acetate in 1 min at ambient temperature.
Steady-state kinetic values were calculated using Hyper (J.S. Easterby, Liverpool University) or GraphPad Prism (GraphPad Software Inc.). Substrate and cofactor concentrations ranged from 0.1 to 10 × K M .
HPLC separation of ATP and ADP. HPLC separation of ATP and ADP was conducted using an Agilent Eclipse XDB column (50 × 4.6 mm 2 ) with isocratic elution using 75% solvent A and 25% solvent B:solvent A, 20 mM tetrabutylammonium phosphate in 10 mM ammonium phosphate buffer pH 4.0; solvent B, acetonitrile. The flow rate was 1 ml min -1 , with detection at 240 nm using a diode array detector (Agilent Technologies, USA). Peaks were eluted at the following retention times: ADP 1.2 min, ATP 1.8 min.
LC-MS analysis of G3P, DHAP and aldol products. G3P and DHAP were separated using a modification of the method used by Hartley et al. 21 ( Supplementary Fig. 8 ). Chromatographic conditions were SIELC ObeliscN column (100 × 2.1 mm 2 ) with isocratic elution using 20% mobile phase A and 80% mobile phase B for 5 min: mobile phase A, 25 mM ammonium formate pH 4.0; mobile phase B, acetonitrile. Mass spectrophotometric detection was conducted using API-ES negative mode with an Agilent 6120 Quadropole LC-MS. Compounds were qualitatively detected by ion scanning in both positive and negative modes using known standards, and then quantified based on selected ion monitoring of relevant ions. G3P was quantified by selected ion monitoring 
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